Silo Pharma Inc.
The patent granted by the USPTO covers the use of biomarkers in determining the efficacy of SPC-15, a targeted prophylactic treatment using ketamine compositions, as a method of treatment for stress-induced affective disorders or stress-induced psychopathology.
Silo's CEO Eric Weisblum says the patent is "an important addition" to the company's IP, by "further protecting the key technology behind SPC-15" in which metabolomic biomarkers predict the response to pharmacological treatments and measure efficacy of the drug on stress-induced affective disorders and Alzheimer's disease, following outcomes from a recent research jointly conducted with Columbia University.
Besides SPC-15, the company's other psychedelic drug candidates include SP-26, or a time-released form of both ketamine and psilocybin; and SPU-21, a new technology that would deliver psilocybin through liposomal homing peptides targeting Rheumatoid Arthritis (RA).
All three are currently undergoing the preclinical stage and expectedly moving into first-in-human trials should outcomes (to be announced around August and September this year) be favorable.
Silo is also advancing a research collaboration agreement with UCSF assessing the effects of psilocybin on inflammatory markers of several diagnosed conditions, including Parkinson's, Bipolar disorder and chronic back pain, through a Phase 1 clinical trial, of which data is expected on or around this September.
